Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Randomized Controlled Trial

NCT04615871 is registered in ClinicalTrials.gov with Vladimír Džavík as lead sponsor.

NCT NCT04615871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04615871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Randomized Controlled Trial
Lead sponsor
Vladimír Džavík
Phase
Phase 2
Overall status
Unknown status
Start date
September 10, 2021
Completion date
March 31, 2022
Enrollment
400 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, myocardial injury